PMID- 22978805
OWN - NLM
STAT- MEDLINE
DCOM- 20130403
LR  - 20221207
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 28
IP  - 10
DP  - 2012 Oct
TI  - Efficacy and safety of valsartan in reducing blood pressure and albuminuria in 
      Chinese patients with essential hypertension: a multicenter prospective 
      open-label observational study.
PG  - 1677-84
LID - 10.1185/03007995.2012.731389 [doi]
AB  - OBJECTIVE: To evaluate the efficacy and safety of 80 or 160 mg/day valsartan in 
      Chinese adult patients with essential hypertension and albuminuria. METHODS: A 
      multicenter prospective open-label observational study was conducted. Adult 
      hypertensive patients with albuminuria were treated with 80 or 160 mg/day 
      valsartan. Blood pressure (BP) was recorded at weeks 4, 8 and 12. Albuminuria was 
      selectively measured at week 12. RESULTS: The intent-to-treat (ITT) population 
      included 1180 patients. Mean sitting systolic BP (MSSBP) and diastolic BP (MSDBP) 
      at baseline was 153.5 [14.41] (mean [SD]) and 88.2 [11.99] (mean [SD]) mmHg. 
      MSSBP and MSDBP at week 4 (mean [SD]: 139.1 [12.02] and 82.2 [8.54] mmHg), week 8 
      (mean [SD]: 135.3 [10.46] and 80.2 [7.55] mmHg) and week 12 (mean [SD]: 132.1 
      [9.80] and 78.1 [6.88] mmHg) were significantly lower than baseline (p < 0.001). 
      The BP control rate of ITT patients at week 12 was 17.8%. Diabetic patients 
      exhibited lower BP control rate than non-diabetic patients (14.0 vs. 22.4%, 
      p < 0.001). A total of 904 patients had albuminuria assessed at week 12. UACR and 
      UAER at week 12 were lower compared with baseline (p < 0.05). In all, 171 
      patients (18.9%) returned to normal albuminuria and albuminuria normalization 
      percentage in diabetic patients exceeded that of non-diabetic patients (26.3 vs. 
      12.1%, p < 0.001). Albuminuria declined by more than 50% in 340 patients (37.6%) 
      and more diabetic patients exhibited such decline in albuminuria than 
      non-diabetic patients (41.7 vs. 33.8%, p < 0.05). No serious drug-related adverse 
      effects (AEs) were observed. LIMITATIONS: Prior antihypertensive treatment before 
      valsartan administration may interfere with the efficacy of subsequent treatment. 
      The discrepancy between 80 and 160 mg may affect patient outcomes and occurrence 
      of AEs. CONCLUSIONS: Valsartan can safely and effectively reduce BP and 
      albuminuria in Chinese adult patients with essential hypertension and 
      albuminuria. Valsartan has the more dramatic effect on albuminuria in diabetic 
      patients than non-diabetic patients.
FAU - Zhang, Xiaoyan
AU  - Zhang X
AD  - Zhongshan Hospital, Shanghai Medical College of Fudan University.
FAU - Ding, Xiaoqiang
AU  - Ding X
FAU - Cao, Guoliang
AU  - Cao G
FAU - Deng, Yueyi
AU  - Deng Y
FAU - Xu, Xudong
AU  - Xu X
FAU - Li, Hui
AU  - Li H
FAU - Zhuang, Xiaoming
AU  - Zhuang X
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20121015
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Aged
MH  - Albuminuria/complications/*drug therapy/physiopathology
MH  - Antihypertensive Agents/*administration & dosage
MH  - Asian People
MH  - Blood Pressure/drug effects
MH  - China
MH  - Diabetes Complications/drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Hypertension/complications/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Tetrazoles/*administration & dosage
MH  - Valine/administration & dosage/*analogs & derivatives
MH  - Valsartan
EDAT- 2012/09/18 06:00
MHDA- 2013/04/04 06:00
CRDT- 2012/09/18 06:00
PHST- 2012/09/18 06:00 [entrez]
PHST- 2012/09/18 06:00 [pubmed]
PHST- 2013/04/04 06:00 [medline]
AID - 10.1185/03007995.2012.731389 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2012 Oct;28(10):1677-84. doi: 10.1185/03007995.2012.731389. 
      Epub 2012 Oct 15.